Hemophagocytic syndrome masquerading as septic shock: An approach to such dilemma

Zakaria Hindi\textsuperscript{1}, Abdallah A Khaled\textsuperscript{2} and Ashraf Abushahin\textsuperscript{3}

Abstract

Introduction: Hemophagocytic syndrome or hemophagocytic lymphohistiocytosis is a rare condition characterized by excessive inflammation that is thought to be caused by the absence of normal downregulation of activated macrophages and lymphocytes. The treatment of hemophagocytic lymphohistiocytosis can depend on whether it is primary or secondary. In secondary hemophagocytic lymphohistiocytosis, the treatment can be directed according to the cause. In general, protocol HLH-94 (which consists of dexamethasone and etoposide in induction and maintenance) has been widely used as it has good outcomes. Hemophagocytic lymphohistiocytosis and septic shock largely overlap which can lead to refractory septic shock and death if not treated. Unfortunately, there is no clear approach for such dilemma. Thereby, we would like to present our case as it has a valuable approach to hemophagocytic lymphohistiocytosis in the setting of sepsis.

Case description: A 60-year-old female, with history of hypertension, came with fever, productive cough, and dyspnea; she was admitted for acute exacerbation of chronic obstructive pulmonary disease and was transferred to intensive care unit for septic shock. The patient progressed to refractory septic shock with no focus of infection. After further investigations, detailed history raised the suspicion of hemophagocytic lymphohistiocytosis; a bone marrow biopsy was collected and confirmed the diagnosis. The patient was on methylprednisolone while waiting for other investigation results and improved markedly. After ruling out secondary causes of hemophagocytic lymphohistiocytosis, she was switched to protocol-94 and continued to improve.

Conclusion: It should be emphasized that septic shock, with or without focus of infection, overlaps with hemophagocytic lymphohistiocytosis and can consequently lead to refractory septic shock and death. Thus, our aim of this case is to encourage further investigations, specifically for hemophagocytic lymphohistiocytosis in the setting of septic shock of unknown origin, to decrease mortality rate. More importantly, early initiation of immunosuppression therapy may be a crucial step before switching to hemophagocytic lymphohistiocytosis-specific treatment.

Keywords

Hemophagocytic syndrome, hemophagocytic lymphohistiocytosis, septic shock of unknown origin

Date received: 13 September 2017; accepted: 14 November 2017

Introduction

Hemophagocytic syndrome or hemophagocytic lymphohistiocytosis (HLH) is a rare condition characterized by excessive inflammation that is caused by the absence of normal downregulation of activated macrophages and lymphocytes, which leads to multi-organ failure. It can be primary (hereditary) or secondary due to malignancies, infections, or immune-related diseases. Diagnosis can be assertively made if at least five out of eight of its diagnostic criteria are met:\textsuperscript{1} (1) splenomegaly; (2) fever \(\geq 38.5^\circ\text{C}\); (3) peripheral blood cytopenia (at least two cell lines); (4) hypertriglyceridemia or/and hypofibrinogenemia; (5) hemophagocytosis in bone marrow, spleen, lymph node, or liver; (6) low or absent NK cell activity; (7) hyperferritinemia; and (8) elevated soluble CD-25.

Taking septic shock into consideration, diagnosing HLH has been a challenge since both conditions overlap and can potentially be life-threatening if not recognized early.\textsuperscript{2}

\textsuperscript{1}Department of Internal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, Odessa, TX, USA
\textsuperscript{2}School of Medicine, The University of Jordan, Amman, Jordan
\textsuperscript{3}Department of Internal Medicine, Cleveland Clinic Foundation-Fairview Hospital, USA

Corresponding Author: Zakaria Hindi, Department of Internal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, 701 West 5th Street, Odessa, TX 79763, USA.
Email: zakaharia.hindi@ttuhsc.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
In general, the treatment approach of secondary HLH should be directed toward suppression of immune system and treating the underlying cause. The current standard treatment regimen of HLH for adults, known as HLH-94 protocol, consists of initial phase of high-dose dexamethasone (10 mg/m²) and etoposide, and maintenance phase of cyclosporin with/without intrathecal methotrexate. However, the management of HLH in the setting of septic shock is challenging since there is no proposed specific approach. As such, we would like to share our experience in a case of HLH in the setting of septic shock origin as it may hold valuable information for future approaches in similar circumstances.

**Case description**

A 60-year-old female, with history of hypertension and chronic obstructive pulmonary disease (COPD), presented with fever, cough, and dyspnea of 2-day duration. Physical examination on admission was significant for tachypnea (respiratory rate was 36 per minute), hypotension (blood pressure was 88/56 mmHg), and confusion. The patient was admitted initially for acute exacerbation of COPD and was started on oxygen through nasal cannula, IV fluids, and IV azithromycin and ceftriaxone which were given after obtaining the cultures. Chest x-ray (CXR) showed no consolidations or infiltrates. Twelve hours after admission, the patient became more hypotensive (78/49 mmHg) and was immediately transferred to the intensive care unit. Her antibiotics regimen was switched to IV piperacillin-tazobactam and levofloxacin, and she was started on vasopressors and hydrocortisone. Three days after admission, despite being on high requirements of vasopressors, broad spectrum antibiotics, and hydrocortisone, the patient showed no improvement and was still febrile (38.9°C). Her cultures (urine, blood, and sputum) from admission showed no growth. Further investigations revealed hypertriglyceridemia (312 mg/dL), thrombocytopenia (30 K/µL), leukopenia (2.6 K/µL), hyperferritinemia (6872 ng/dL), hypofibrinogenemia (69 mg/dL), normal coagulation profile, normal procalcitonin, and negative work-up for connective tissue diseases (including anti-nuclear antibody and rheumatoid factor) and viral infections (including hepatitis A/B/C viruses, human immunodeficiency virus, cytomegalovirus, parvovirus 19, and Epstein–Barr virus). Peripheral blood smear was unremarkable as well.

Family history was significant for malignancies in her first-degree relatives (lung and brain malignancies). Thus, a computerized tomography scan without contrast (due to renal failure) was performed for chest, abdomen, and pelvis, which revealed moderate splenomegaly. HLH was highly suspected, and therefore, soluble cluster differentiation 25 (CD-25) sent which was elevated (1521 U/mL). A bone marrow aspirate was also performed and showed hemophagocytosis (Figure 1(a) and (b)). It was decided to start the patient on IV methylprednisolone (2 mg/kg/day) while waiting for flow cytometry testing and cytogenetics results. Three days after the methylprednisolone was started, the patient improved markedly and was no longer in septic shock. One week later, the results of flow cytometry and cytogenetics were negative for any lymphomas or leukemias; thus, the patient was switched to HLH-94 protocol (high dose of dexamethasone and etoposide). One week after initiation of the protocol, her mean arterial pressure was maintained above 65 mmHg and had not developed any episodes of fever (Table 1 summarizes the trend of the important laboratory values and sequential organ failure assessment (SOFA) score). The patient was transferred then to medical floor and was discharged on dexamethasone and etoposide, and was advised to follow up closely with Hematology–Oncology Outpatient Clinics.

**Discussion**

After literature review, only one case report was extensively described, by Maheshwari et al., in which a patient was diagnosed with HLH after presenting with septic shock of unknown origin. Although their patient was eventually diagnosed with HLH, the patient deteriorated and developed more complications. Their patient had similar findings and course of progression as ours. However, we initiated steroid treatment for our
Table 1. Trend of the important laboratory values and SOFA score.

|                | Day 1      | Day 2      | Day 3      |
|----------------|------------|------------|------------|
| Hb             | 12.1 g/dL  | 10.2 g/dL  | 11.3 g/dL  |
| WBC            | 5.3 K/µL   | 2.6 K/µL   | 7.2 K/µL   |
| Platelets      | 35,000 /µL | 25,000 /µL | 53,000 /µL |
| INR            | 1.44       | 2.09       | 1.12       |
| Fibrinogen     | Not sent   | 69 mg/dL   | 220 mg/dL  |
| AST            | 66 U/L     | 143 U/L    | 43 U/L     |
| ALT            | 44 U/L     | 112 U/L    | 32 U/L     |
| ALKP           | 154 U/L    | 539 U/L    | 124 U/L    |
| Total bilirubin| 1.2 mg/dL  | 1.6 mg/dL  | 0.9 mg/dL  |
| Procalcitonin  | 1.2 ng/mL  | 1.76 ng/mL | 0.4 ng/mL  |
| CRP            | 11 mg/L    | 33 mg/L    | 8 mg/L     |
| SOFA score     | 8 points   | 11 points  | 4 points   |

Hb: hemoglobin; WBC: white blood cells; INR: international normalized ratio; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALKP: alkaline phosphatase; CRP: C-reactive protein; SOFA: sequential organ failure assessment.

improvement in our patient on methylprednisolone as cytokines level would be expected to be high with HLH.

Conclusion

It should be emphasized that septic shock, with or without focus of infection, overlaps with HLH. This combination can consequently lead to refractory septic shock and death. Thus, our aim with this case is to encourage implementing a special protocol for further investigations, specifically assessing for HLH in the setting of refractory septic shock, which can effectively decrease the mortality rate if treated. More importantly, initiation of immunosuppression therapy might be a crucial step before initiating other specific treatments, such as HLH-94 protocol. Our recommendations to diagnose HLH in the setting of sepsis is to send for soluble CD-25 and ferritin level as these markers have higher sensitivity compared to other diagnostic criteria.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Our institution does not require ethical approval for reporting individual cases or case series.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Zakaria Hindi http://orcid.org/0000-0003-0222-2312

Informed consent

Verbal and written consents were obtained from the patient(s) for their anonymized information to be published in this article.

References

1. Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2011; 118: 4041–4052.
2. Zhang Z, Hong Y, Smischney NJ, et al. Early management of sepsis with emphasis on early goal directed therapy: AME evidence series 002. J Thorac Dis 2017; 9(2): 392–405
3. Raschke RA and Garcia-Orr R. Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults. Chest 2011; 140: 933–938.
4. Kleyberg RL and Schiller GJ. Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol 2012; 10: 726–732.
5. Maheshwari N, Mandal AK and Sahni N. Sepsis of unknown origin with multiorgan failure syndrome: think of hemophagocytic lymphohistiocytosis. Indian J Crit Care Med 2015; 19: 419–421.
6. Agarwal A and Agarwal A. Infection associated secondary hemophagocytic lymphohistiocytosis in sepsis syndromes—a tip of an iceberg. *J Assoc Physicians India* 2016; 64(10): 44–50.

7. Allen CE, Yu X, Kozinetz CA, et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2008; 50: 1227–1235.

8. Janka G. Hemophagocytic lymphohistiocytosis: when the immune system runs amok. *Klin Pädiatr* 2009; 221: 278–285.

9. Bentzer P, Fjell C, Walley KR, et al. Plasma cytokine levels predict response to corticosteroids in septic shock. *Intensive Care Med* 2016; 42: 1970–1979.